104 related articles for article (PubMed ID: 23328831)
21. The deadly impact of extreme drug resistance in Acinetobacter baumannii.
Spellberg B; Bonomo RA
Crit Care Med; 2014 May; 42(5):1289-91. PubMed ID: 24736340
[No Abstract] [Full Text] [Related]
22. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with acinetobacter bacteremia.
Chuang YC; Sheng WH; Li SY; Lin YC; Wang JT; Chen YC; Chang SC
Clin Infect Dis; 2011 Feb; 52(3):352-60. PubMed ID: 21193494
[TBL] [Abstract][Full Text] [Related]
23. Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia.
Liu CP; Shih SC; Wang NY; Wu AY; Sun FJ; Chow SF; Chen TL; Yan TR
J Microbiol Immunol Infect; 2016 Dec; 49(6):934-940. PubMed ID: 25553994
[TBL] [Abstract][Full Text] [Related]
24. Synergistic activity of sulbactam combined with colistin against colistin-resistant Acinetobacter baumannii.
Kempf M; Djouhri-Bouktab L; Brunel JM; Raoult D; Rolain JM
Int J Antimicrob Agents; 2012 Feb; 39(2):180-1. PubMed ID: 22100281
[No Abstract] [Full Text] [Related]
25. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii.
Schafer JJ; Goff DA; Stevenson KB; Mangino JE
Pharmacotherapy; 2007 Jul; 27(7):980-7. PubMed ID: 17594203
[TBL] [Abstract][Full Text] [Related]
26. Risk factors for carbapenem-resistant Acinetobacter baumanii blood stream infections in a neonatal intensive care unit, Delhi, India.
Kumar A; Randhawa VS; Nirupam N; Rai Y; Saili A
J Infect Dev Ctries; 2014 Aug; 8(8):1049-54. PubMed ID: 25116673
[TBL] [Abstract][Full Text] [Related]
27. Risk factors and clinical outcomes of multidrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Thailand.
Anunnatsiri S; Tonsawan P
Southeast Asian J Trop Med Public Health; 2011 May; 42(3):693-703. PubMed ID: 21706949
[TBL] [Abstract][Full Text] [Related]
28. Community-acquired bloodstream infections caused by Acinetobacter baumannii: A matched case-control study.
Chen CT; Wang YC; Kuo SC; Shih FH; Chen TL; How CK; Yang YS; Lee YT
J Microbiol Immunol Infect; 2018 Oct; 51(5):629-635. PubMed ID: 28701266
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of carbapenem-resistant Acinetobacter baumannii from 2005 to 2016 in Switzerland.
Ramette A; Kronenberg A;
BMC Infect Dis; 2018 Apr; 18(1):159. PubMed ID: 29614963
[TBL] [Abstract][Full Text] [Related]
30. Exposure to quinolones is associated with carbapenem resistance among colistin-susceptible Acinetobacter baumannii blood isolates.
Kopterides P; Koletsi PK; Michalopoulos A; Falagas ME
Int J Antimicrob Agents; 2007 Nov; 30(5):409-14. PubMed ID: 17851052
[TBL] [Abstract][Full Text] [Related]
31. The authors reply.
Lee HY; Chiu CH
Crit Care Med; 2014 Sep; 42(9):e628-9. PubMed ID: 25126811
[No Abstract] [Full Text] [Related]
32. Two case reports of gastroendoscopy-associated Acinetobacter baumannii bacteremia.
Chen CH; Wu SS; Huang CC
World J Gastroenterol; 2013 May; 19(18):2835-40. PubMed ID: 23687423
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcomes of children with carbapenem-resistant Acinetobacter baumannii bacteremia.
Vandepitte WP; Berge J; Andersson R
J Med Assoc Thai; 2014 Nov; 97 Suppl 11():S129-39. PubMed ID: 25509707
[TBL] [Abstract][Full Text] [Related]
34. [In vitro tigecycline and carbapenem susceptibilities of clinical Acinetobacter baumannii isolates].
Nayman Alpat S; Aybey AD; Akşit F; Ozgüneş I; Kiremitçi A; Usluer G
Mikrobiyol Bul; 2010 Oct; 44(4):641-5. PubMed ID: 21063976
[TBL] [Abstract][Full Text] [Related]
35. Comparison of pneumonia- and non-pneumonia-related Acinetobacter baumannii bacteremia: Impact on empiric therapy and antibiotic resistance.
Teng SO; Yen MY; Ou TY; Chen FL; Yu FL; Lee WS
J Microbiol Immunol Infect; 2015 Oct; 48(5):525-30. PubMed ID: 25103719
[TBL] [Abstract][Full Text] [Related]
36. Nosocomial infection of multidrug-resistant Acinetobacter baumannii in Thailand.
Anudit C; Kooltheat N; Potup P; Pankla Sranujit R; Usuwanthim K
Am J Infect Control; 2016 Oct; 44(10):1161-1163. PubMed ID: 27375062
[TBL] [Abstract][Full Text] [Related]
37. Bloodstream infections caused by Acinetobacter species with reduced susceptibility to tigecycline: clinical features and risk factors.
Park GE; Kang CI; Cha MK; Cho SY; Seok H; Lee JH; Kim JY; Ha YE; Chung DR; Peck KR; Lee NY; Song JH
Int J Infect Dis; 2017 Sep; 62():26-31. PubMed ID: 28676346
[TBL] [Abstract][Full Text] [Related]
38. Multidrug-resistant Acinetobacter baumannii bacteremia treated with tigecycline in two pediatric burn patients.
Kanık-Yüksek S; Tezer H; Ozkaya-Parlakay A; Gulhan B; Sayed-Oskovi H; Kara A; Şenel E
Pediatr Infect Dis J; 2015 Jun; 34(6):677. PubMed ID: 25970113
[No Abstract] [Full Text] [Related]
39. CHROMagar Acinetobacter is not selective for carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex.
Akers KS; Barsoumian A; Beckius ML; Murray CK; Mende K
Diagn Microbiol Infect Dis; 2010 Jun; 67(2):209-11. PubMed ID: 20466197
[No Abstract] [Full Text] [Related]
40. Mortality associated with Acinetobacter baumannii complex bacteremia among patients with war-related trauma.
Kang G; Hartzell JD; Howard R; Wood-Morris RN; Johnson MD; Fraser S; Weintrob A; Wortmann G
Infect Control Hosp Epidemiol; 2010 Jan; 31(1):92-4. PubMed ID: 19929690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
